Lilly’s Alimta recommended by CHMP


Eli Lilly has received a positive opinion from the CHMP for Alimta as continuation maintenance therapy of advanced nonsquamous non-small cell lung cancer (NSCLC).

The recommendation is for the pemetrexed injection to be used as part of maintenance therapy, a relatively new concept in lung cancer treatment to commence immediately after patients have completed first-line treatment, in an effort to sustain disease control.

Dr Allen Melemed, Senior Medical Director of Alimta at Lilly Oncology, said: “Lung cancer is one of the most difficult cancers to treat and new therapy options are much needed.”

The CHMP’s recommendation will be reviewed by the European Commission, which will decide whether to approve the treatment for indication in Europe.

Dr Melemed commented: “If approved, Alimta would be the first tailored treatment option based on efficacy that can potentially extend lives beginning in first-line treatment and continuing through maintenance in advanced nonsquamous non-small cell lung cancer.”

No chemotherapy is currently approved as ‘continuation maintenance’ treatment. Currently approved lung cancer maintenance therapies use different medicines in the first-line and maintenance phases of treatment.

The CHMP's opinion was based on clinical research results from Paramount, a randomised, double-blind Phase III study involving patients with advanced nonsquamous NSCLC. Participants received initial therapy with four cycles of Alimta plus cisplatin. Patients whose disease did not progress continued to the maintenance phase, where survival was assessed in patients who received Alimta plus best supportive care (BSC), compared with those who received a placebo plus BSC.

Alimta is already approved in the first-line, maintenance and second-line settings in the EU and US for the indication. The treatment was originally recommended by NICE in September 2009 to treat the cancer on the NHS in the UK, but reversed its decision in December 2009, citing data uncertainties. NICE came to a final recommendation in June 2010.

Lung cancer is the most common form of cancer in the world, causing 1.3 million cancer deaths each year. NSCLC contributes to 85-90% of all lung cancers.

Make a comment

To voice your opinion, please Log in or Register.

Recent comments (10)

  • ratownik medyczny

    You have observed very interesting points ! ps nice internet site .

  • Bernardo Garnick

    F*ckin’ amazing things here. I’m very glad to look your post. Thanks so much and i'm looking forward to contact you. Will you please drop me a e-mail?

  • интернет казино

    Get serious guys!

  • Free Porn

    I am not sure where you’re getting your information, but good topic. I needs to spend some time learning much more or understanding more. Thanks for magnificent info I was looking for this information for my mission.

  • Sukienki

    I?m not sure where you're getting your info, but great topic. I needs to spend some time learning much more or understanding more. Thanks for fantastic info I was looking for this info for my mission.

  • Speed Study

    I was happy to find this web-site.I wantedHello! I just would like to give a huge thumbs up for the great info you have here on this post. I will be coming back to your blog for more soon.

  • Christopher Vaulx

    Your writing is great:)

  • Jim Stevens

    Yes I agree with this completely. John New Accounts Manager <A href=""></A>

  • youjizz

    You really make it seem so easy with your presentation but I find this matter to be really something which I think I would never understand. It seems too complex and extremely broad for me. I am looking forward for your next post, I will try to get the hang of it!

  • Grace Schnorr

    hanks for the marvelous posting! I really enjoyed reading it, you may be a great author.I will ensure that I bookmark your blog and may come back in the future. I want to encourage continue your great work, have a nice afternoon!